Spyre (SYRE) CFO Scott Burrows Exercises Options, Sells Shares

What Happened
Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics (SYRE), exercised 7,500 equity awards at $14.50 per share (cash cost $108,750) on August 3, 2026, and sold a total of 7,500 shares in open-market transactions the same day for roughly $716,771 in aggregate proceeds. The Form 4 also reports a separate derivative disposition of 7,500 shares at $0 (a technical reporting item related to the exercise/conversion).

Key Details

• Transaction date: August 3, 2026; Form 4 filed August 5, 2026 (timely filing).
• Exercise: 7,500 shares at $14.50 = $108,750 cash paid.
• Sales (open-market): 5,100 shares at a weighted avg $95.21 (prices ranged $94.84–$95.83) = $485,571; 2,300 shares at weighted avg $96.30 (prices ranged $95.85–$96.82) = $221,490; 100 shares at $97.10 = $9,710. Total sale proceeds ≈ $716,771.
• A derivative line shows 7,500 shares disposed at $0 (reported separately in the filing).
• Sales were executed pursuant to a Rule 10b5-1 trading plan adopted November 10, 2025.
• Holdings noted in the filing: 67,476 restricted stock units (RSUs) and an option to purchase 404,857 shares (post 1-for-25 reverse split adjustment); the filing excerpt does not state total common shares owned after these transactions.

Context

• This was an exercise of options followed by immediate open-market sales (common practice to cover exercise cost, taxes, or to diversify). The presence of a 10b5-1 plan indicates the sales were pre-arranged.
• Purchases (exercises) can be interpreted as acquisition of shares, but the simultaneous sales mean no long-term accumulation is shown here.
• The filing is factual and does not indicate management’s intent or future expectations.